Vancomycin in peritoneal dialysis-associated peritonitis

Seminars in Dialysis

Volumn 9, Issue 5, 1996, Pages 417-423

  Bailie, George R ^a   Eisele, George ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000228457     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139x.1996.tb00879.x     Document Type: Article

References (65)

1. Mairoca R, Cancarini GC, Brunori G, Camerini C, Manili L: Morbidity and mortality of CAPD and hemodialysis. Kidney Int 43(Suppl 40):S4-S15, 1993
2. Piraino B, Bernardini J, Holley SL, Perlmutter JA: A comparison of peritoneal dialysis-related infections in short- and long-term peritoneal dialysis patients. Perit Dial Int 13:194-197, 1993
3. Keane WF, Everett ED, Golper TA, Gokal R, Halstenson C, Kawaguchi I, Riella M, Vas S, Verbrugh HA: Peritoneal dialysis-related peritonitis treatment recommendations: 1993 update. Perit Dial Int 13:14-28, 1993
4. Bailie GR, Venezia RA, Eisele G: Turbid dialysate effluent and peritonitis. Clin Nephrol 36:156-157, 1991
5. Vas SI: Treatment of peritonitis. Perit Dial Int 14(Suppl 3):S49-S55, 1994
6. Millikin SP, Matzke GR, Keane WF: Antimicrobial treatment of peritonitis associated with CAPD. Perit Dial Int 11:252-260, 1991
7. Dryden MS, Wing AJ, Phillips I: Low dose intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving CAPD. J Antimicrob Chemother 28:131-139, 1991
8. Grefberg N, Danielson BG, Nilsson P: Peritonitis in patients on CAPD. Scand J Infect Dis 16:187-193, 1984
9. Saklayen MG: CAPD peritonitis. Med Clin N Am 74:997-1010, 1990
10. Bailie GR, Morton R, Ganguli L, Keaney M, Waldek S: Intravenous or intraperitoneal vancomycin for the treatment of CAPD associated gram-positive peritonitis? Nephron 46:316-318, 1987
11. Morse GD, Farolino DF, Apicella MA, Walshe JJ: Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during CAPD. Antimicrob Agents Chemother 31:171-177, 1987
12. Bastani B, Freer K, Read D, Bailey S, Sherman RA, Davis M, Engels D, Westervelt FB: Treatment of gram-positive peritonitis with two intraperitoneal doses of vancomycin in CAPD patients. Nephron 45: 283-285, 1987
13. Boyce NW, Wood C, Thomson NM, Kerr P, Atkins RC: Intraperitoneal vancomycin therapy for CAPD peritonitis - a prospective, randomized comparison of intermittent v continuous therapy. Am J Kidney Dis 12:3O4-306, 1988
14. Beaman M, Solaro L, McGonigle RJS, Michael J, Adu D: Vancomycin and ceftazidime in the treatment of CAPD peritonitis. Nephron 51:51-55, 1989
15. Flanigan MJ, Lim VS: Initial treatment of dialysis associated peritonitis: A controlled trial of vancomycin versus cefazolin. Perit Dial Int 11:31-37, 1991
16. Friedland JS, Iveson TJ, Fraise AP, Winearls CG, Selkon JB, Oliver DO: A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with CAPD. J Antimicrob Chemother 26(Suppl F):77-81, 1990
17. Bennett-Jones DN, Russell GI, Barrett A: A comparison between oral ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of CARD peritonitis. J Antimicrob Chemother 26(Suppl F):73-76, 1990
18. Tapson JS, Orr KE, George JC, Stanfield E, Bint AJ, Ward MK: A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis. J Antimicrob Chemother 26(Suppl F):63-71, 1990
19. Moellering RC, Krogstad DJ, Greenblatt DJ: Vancomycin therapy in patients with impaired renal function: A nomogram for dosage. Ann Int Med 94:343-346, 1981
20. Rotschafer JG, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD: Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 22:391-394, 1982
21. Matzke GR, McGory RW, Halstenson CE, Keane WF: Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433-437, 1984
22. Rodvold KA, Blum RA, Fischer JA, Zokufa HZ, Rotschafer JC, Crossley KB, Riff LJ: Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 32: 848-852, 1988
23. Tan CC, Lee HS, Ti TY, Lee EJC: Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit 12:29-34, 1990
24. Pancorbo S, Comty C: Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis. Nephron 31:37-39, 1982
25. Bailie GR, Eisele G, Venezia RA, Yocum D, Hollister A: Prediction of serum vancomycin concentrations following intraperitoneal loading doses in CAPD patients with peritonitis. Clin Pharmacokinet 22:298-307, 1992
26. Lanese DM, Alfrey PS, Molitoris BA: Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 35:1409-1412, 1989
27. Torras J, Cao C, Rivas MC, Cano M, Fernandez E, Montoliu J: Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 36:35-41, 1991
28. Quale JM, O'Halloran JJ, DeVincenzo N, Barth RH: Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother 36:1424-1426, 1992
29. DeSoi CA, Sahm DF, Umans JG: Vancomycin elimination during high-flux hemodialysis: Kinetic model and comparison of four membranes. Am J Kidney Dis 20:354-360, 1992
30. Cantu TG, Yamanaka-Yuen NA, Lietman PS: Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 18:533-543, 1994
31. Bailie GR, Neal D: Vancomycin ototoxicity and nephrotoxicity: A review. Med Toxicol 3:376-386, 1988
32. Eisele G, Adewunni C, Bailie GR, Yocum D, Venezia R: Surreptitious use of antimicrobial agents by CAPD patients. Perit Dial Int 13:313-315, 1993
33. Rogge MC, Johnson CA, Zimmerman SW, Welling PG: Vancomycin disposition during CAPD: A pharmacokinetic analysis of peritoneal drug transport. Antimicrob Agents Chemother 27:578-582, 1985
34. Morse GD, Apicella MA, Walshe JJ: Absorption of intraperitoneal antibiotics. Drug Intell Clin Pharm 22:58-61, 1988
35. Magera BE, Arroyo JC, Rosansky SJ, Postic B: Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis. Antimicrob Agents Chemother 23:710-714, 1983
36. Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Vancomycin kinetics during CAPD. Clin Pharmacol Ther 34:631-637, 1983
37. Blevins RD. Halstenson CE, Salem NG, Matzke GR: Pharmacokinetics of vancomycin in patients undergoing CAPD. Antimicrob Agents Chemother 25:603-606, 1984
38. Harford AM, Sica DA, Tartaglione T, Polk RE, Dalton HP, Poynor W: Vancomycin pharmacokinetics in CAPD patients with peritonitis. Nephron 43:217-222, 1986
39. Bastani B, Spyker DA, Westervelt FB: Peritoneal absorption of vancomycin during and after resolution of peritonitis in CAPD patients. Perit Dial Int 8:135-136, 1988
40. Rubin J: Vancomycin absorption from the peritoneal cavity during dialysis-related peritonitis. Perit Dial Int 10:283-285, 1990
41. O'Brien M, Mason NA: Systemic absorption of intraperitoneal antimicrobials in CAPD. Clin Pharm 11:246-256, 1992
42. Maher JF: Pharmacological considerations for peritoneal dialysis Perit Dial Int 13(Suppl 2):S363-S366, 1993
43. Keller E, Reetze P, Schollmeyer P: Drug therapy in patients undergoing CAPD: Clinical pharmacokinetic considerations. Clin Pharmacokinet 18:104-117, 1990
44. Bailie GR, Eisele G: Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis peritonitis. J Antimicrob Chemother 35:563-567, 1995
45. Were AJ, Mansden A, Tooth A, Ramsden R, Mistry CD, Gokal R: Netilmicin and vancomycin in the treatment of peritonitis in CAPD patients. Clin Nephrol 37:209-213, 1992
46. Gorman T, Eisele G, Bailie GR: Intraperitoneal antibiotics effectively treat non-dialysis-related infections. Perit Dial Int 15:283-284, 1995
47. Johnson CA: Intraperitoneal vancomycin administration. Perit Dial Int 11:9-11, 1991
48. Piraino B, Bernardini J, Johnston J, Sorkin M: Chemical peritonitis due to intraperitoneal vancomycin (Vancoled). Perit Dial Bull 7:156-159, 1987
49. Abel SR: Lack of chemical peritonitis after intraperitoneal use of two brands of vancomycin hydrochloride. Clin Pharm 8:91-92, 1989
50. Newman L, Friedlander M, Tessman M: More experience with Vancoled induced chemical peritonitis. Perit Dial Int 10:182, 1990
51. Freiman JP, Graham DJ, Reed TG, McGoodwin EB: Chemical peritonitis following intraperitoneal administration of vancomycin. Perit Dial Int 12:57-60, 1992
52. Smith TA, Bailie GR, Eisele G: Chemical peritonitis associated with intraperitoneal vancomycin. DICP Ann Pharmacother 25:602-603, 1991
53. Bailie GR, Kowalsky SF, Eisele G: Red-neck syndrome associated with intraperitoneal vancomycin. Clin Pharm 9:671-672, 1990
54. Millikin SP, Matzke GR, Keane WF: Antimicrobial treatment of peritonitis associated with CAPD. Perit Dial Int 11:252-260, 1991
55. Rotellar C, Zarinetchi F, Mazzoni MJ, Bauer A, Rakowski TA, Winchester JF: Vancomycin and aztreonam versus vancomycin and ceftazidime for the treatment of peritonitis in patients on CAPD. Perit Dial Int 13(Suppl 1):S21, 1993
56. Dharmasena AD, Coles GA, Hourahane G, Richards T: A controlled trial of two different vancomycin regimes. Adv Perit Dial 4:163-164, 1988
57. Nye KJ, Gibson SP, Nwosu AC, Manji MR, Robinson BHB, Hawkins JB: Single-dose intraperitoneal vancomycin and oral ciprofloxacin for the treatment of peritonitis in CAPD patients: Preliminary report. Perit Dial Int 13:59-60, 1993
58. Brown J, Altmann P, Cunningham J, Shaw E, Marsh F: Pharmacokinetics of once daily intraperitoneal aztreonam and vancomycin in the treatment of CAPD peritonitis. J Antimicrob Chemother 25:141-147, 1990
59. Bailie GR, Haqqie SS, Eisele G, German T, Low C: Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis. Perit Dial Int 15:269-271, 1995
60. Bailie GR, Kane MP: Stability of drug additives to peritoneal dialysate. Perit Dial Int 15:328-335, 1995
61. Vaughan LM, Poon CY: Stability of ceftazidime and vancomycin alone and in combination in heparinized and nonheparinized peritoneal dialysis solution. Ann Pharmacother 28:572-576, 1994
62. Drake JM, Myre SA, Staneck JL, et al.: Antimicrobial activity of vancomycin, gentamicin, and tobramycin in peritoneal dialysis solution. Am J Hosp Pharm 47:1604-1606, 1990
63. Sewell DL, Golper TA: Stability of antimicrobial agents in peritoneal dialysate. Antimicrob Agents Chemother 21:528-529, 1982
64. Mawhinney WM, Adair CG, Gorman SP, et al.: Stability of vancomycin hydrochloride in peritoneal dialysis solution. Am J Hosp Pharm 49:137-139, 1992
65. Sewell DL, Golper TA, Brown SD, et al.: Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin. Am J Kidney Dis 3:209-212, 1983